

---

## Bibliography

---

- [1] Mettler Toledo. Polymerization reactions. URL [https://www.mt.com/au/en/home/applications/L1\\_AutoChem\\_Applications/L2\\_ReactionAnalysis/L2\\_Polymerization.html#publications](https://www.mt.com/au/en/home/applications/L1_AutoChem_Applications/L2_ReactionAnalysis/L2_Polymerization.html#publications).
  - [2] Wikipedia. Liposome. URL <https://en.wikipedia.org/wiki/Liposome>.
  - [3] Schoonen, L. & van Hest, J. C. M. Functionalization of protein-based nanocages for drug delivery applications. *Nanoscale* **6**, 7124–7141 (2014). URL <http://xlink.rsc.org/?DOI=C4NR00915K>.
  - [4] A Blair, J. M., Webber, M. A., Baylay, A. J., Ogbolu, D. O. & V Piddock, L. J. Molecular mechanisms of antibiotic resistance. *Nature Publishing Group* **13** (2014). URL <https://www.nature.com/nrmicro/journal/v13/n1/pdf/nrmicro3380.pdf>.
  - [5] Kim, J. Phage as a therapeutic agent. URL <https://medium.com/@thryve/phage-as-a-therapeutic-agent-ed4c466302e5>.
  - [6] Torres, M. D., Sothiselvam, S., Lu, T. K. & de la Fuente-Nunez, C. Peptide Design Principles for Antimicrobial Applications. *Journal of Molecular Biology* (2019). URL <https://www.sciencedirect.com/science/article/pii/S0022283618312890>.
  - [7] Nguyen, L. T., Haney, E. F. & Vogel, H. J. The expanding scope of antimicrobial peptide structures and their modes of action. *Trends in Biotechnology* **29**, 464–472 (2011). URL <https://www.sciencedirect.com/science/article/pii/S0167779911000886?via=ihub>.
-

- 
- [8] Castelletto, V. *et al.* Structurally plastic peptide capsules for synthetic antimicrobial viruses. *Chem. Sci.* **7**, 1707–1711 (2016). URL <http://xlink.rsc.org/?DOI=C5SC03260A>.
- [9] Masaoka, Y., Tanaka, Y., Kataoka, M., Sakuma, S. & Yamashita, S. Site of drug absorption after oral administration: Assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract. *European Journal of Pharmaceutical Sciences* **29**, 240–250 (2006). URL <https://www.sciencedirect.com/science/article/pii/S0928098706001709?via%3Dihub>.
- [10] Mitragotri, S., Burke, P. A. & Langer, R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. *Nature Reviews Drug Discovery* **13**, 655–672 (2014). URL <http://www.nature.com/articles/nrd4363>.
- [11] Krol, S. Challenges in drug delivery to the brain: Nature is against us. *Journal of Controlled Release* **164**, 145–155 (2012). URL <https://www.sciencedirect.com/science/article/pii/S0168365912003999>.
- [12] Pattni, B. S. & Torchilin, V. P. Targeted Drug Delivery Systems: Strategies and Challenges. 3–38 (Springer, Cham, 2015). URL [http://link.springer.com/10.1007/978-3-319-11355-5\\_1](http://link.springer.com/10.1007/978-3-319-11355-5_1).
- [13] Jain, S. & Edwards, M. J. Advances and challenges in the development of drug delivery systems - A European perspective (2016). URL <https://www.semanticscholar.org/paper/Advances-and-challenges-in-the-development-of-drug-Jain-Edwards/51a16060d641078aac675e3a9c2ab8e7b1effbfa>.
- [14] Hughes, G. A. Nanostructure-mediated drug delivery. *Nanomedicine: Nanotechnology, Biology and Medicine* **1**, 22–30 (2005). URL <https://www.sciencedirect.com/science/article/pii/S1549963405000122?via%3Dihub>.
- [15] Singh, P. *et al.* Gold Nanoparticles in Diagnostics and Therapeutics for Human Cancer. *International journal of molecular sciences* **19** (2018). URL <http://www.ncbi.nlm.nih.gov/pubmed/29986450>.
-

- 
- [16] Boisselier, E. & Astruc, D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. *Chemical Society Reviews* **38**, 1759 (2009). URL <http://xlink.rsc.org/?DOI=b806051g>.
- [17] Erol, O. *et al.* Recent Advances in Bioactive 1D and 2D Carbon Nanomaterials for Biomedical Applications. *Nanomedicine: Nanotechnology, Biology and Medicine* (2017). URL <http://linkinghub.elsevier.com/retrieve/pii/S1549963417300898>.
- [18] Depan, D., Shah, J. & Misra, R. Controlled release of drug from folate-decorated and graphene mediated drug delivery system: Synthesis, loading efficiency, and drug release response. *Materials Science and Engineering: C* **31**, 1305–1312 (2011). URL <https://www.sciencedirect.com/science/article/pii/S0928493111001159>.
- [19] Lammers, T. *et al.* Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. *Biomaterials* **30**, 3466–3475 (2009). URL <https://linkinghub.elsevier.com/retrieve/pii/S0142961209002324>.
- [20] Liechty, W. B., Kryscio, D. R., Slaughter, B. V. & Peppas, N. A. Polymers for drug delivery systems. *Annual review of chemical and biomolecular engineering* **1**, 149–73 (2010). URL <http://www.ncbi.nlm.nih.gov/pubmed/22432577>.
- [21] Kawakatsu, T. *Statistical Physics of Polymers : an Introduction* (Springer Berlin Heidelberg, 2004).
- [22] Nicolas, J., Mura, S., Brambilla, D., Mackiewicz, N. & Couvreur, P. Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. *Chem. Soc. Rev.* **42**, 1147–1235 (2013). URL <http://xlink.rsc.org/?DOI=C2CS35265F>.
- [23] Nair, L. S. & Laurencin, C. T. Biodegradable polymers as biomaterials. *Progress in Polymer Science* **32**, 762–798 (2007). URL <https://www.sciencedirect.com/science/article/pii/S0079670007000664>.
-

- 
- [24] Rao, S. H., Harini, B., Shadamarshan, R. P. K., Balagangadharan, K. & Selvamurugan, N. Natural and synthetic polymers/bioceramics/bioactive compounds-mediated cell signalling in bone tissue engineering. *International journal of biological macromolecules* **110**, 88–96 (2018). URL <http://www.ncbi.nlm.nih.gov/pubmed/28917940>.
- [25] Yoo, J.-W., Irvine, D. J., Discher, D. E. & Mitragotri, S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. *Nature Reviews Drug Discovery* **10**, 521–535 (2011). URL <http://www.nature.com/articles/nrd3499>.
- [26] Yingchoncharoen, P., Kalinowski, D. S. & Richardson, D. R. Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. *Pharmacological reviews* **68**, 701–87 (2016). URL <http://www.ncbi.nlm.nih.gov/pubmed/27363439>.
- [27] Bunker, A., Magarkar, A. & Viitala, T. Rational design of liposomal drug delivery systems, a review: Combined experimental and computational studies of lipid membranes, liposomes and their PEGylation. *BBA - Biomembranes* **1858**, 2334–2352 (2016). URL <http://dx.doi.org/10.1016/j.bbamem.2016.02.025>.
- [28] Pattni, B. S., Chupin, V. V. & Torchilin, V. P. New Developments in Liposomal Drug Delivery. *Chemical Reviews* **115**, 10938–10966 (2015). URL <http://pubs.acs.org/doi/10.1021/acs.chemrev.5b00046>.
- [29] Jain, S. & Pillai, J. Bacterial membrane vesicles as novel nanosystems for drug delivery. *International journal of nanomedicine* **12**, 6329–6341 (2017). URL <http://www.ncbi.nlm.nih.gov/pubmed/28919737>.
- [30] Linko, V., Ora, A. & Kostainen, M. A. DNA Nanostructures as Smart Drug-Delivery Vehicles and Molecular Devices. *Trends in Biotechnology* **33**, 586–594 (2015). URL <https://www.sciencedirect.com/science/article/pii/S0167779915001614>.
- [31] Douglas, S. M., Bachelet, I. & Church, G. M. A Logic-Gated Nanorobot for Targeted Transport of Molecular Payloads. *Science* **335**, 831–
-

- 834 (2012). URL <http://www.sciencemag.org/cgi/doi/10.1126/science.1214081>.
- [32] Zhang, Q. *et al.* DNA Origami as an *In Vivo* Drug Delivery Vehicle for Cancer Therapy. *ACS Nano* **8**, 6633–6643 (2014). URL <http://pubs.acs.org/doi/10.1021/nn502058j>.
- [33] Jiang, Q. *et al.* DNA Origami as a Carrier for Circumvention of Drug Resistance. *Journal of the American Chemical Society* **134**, 13396–13403 (2012). URL <http://pubs.acs.org/doi/10.1021/ja304263n>.
- [34] Lobo, F. P. *et al.* Virus-Host Coevolution: Common Patterns of Nucleotide Motif Usage in Flaviviridae and Their Hosts. *PLoS ONE* **4**, e6282 (2009). URL <http://dx.plos.org/10.1371/journal.pone.0006282>.
- [35] Lauer, K. B., Borrow, R. & Blanchard, T. J. Multivalent and Multipathogen Viral Vector Vaccines. *Clinical and Vaccine Immunology* **24**, e00298–16 (2017). URL <https://cvi.asm.org/content/24/1/e00298-16>.
- [36] Daya, S. & Berns, K. I. Gene therapy using adeno-associated virus vectors. *Clinical microbiology reviews* **21**, 583–93 (2008). URL <http://www.ncbi.nlm.nih.gov/pubmed/18854481>.
- [37] Büning, H. & Schmidt, M. Adeno-associated Vector Toxicity-To Be or Not to Be? *Molecular therapy : the journal of the American Society of Gene Therapy* **23**, 1673–1675 (2015). URL <http://www.ncbi.nlm.nih.gov/pubmed/26606658>.
- [38] Smalley, E. First AAV gene therapy poised for landmark approval. *Nature Biotechnology* **35**, 998–999 (2017). URL <http://www.nature.com/articles/nbt1117-998>.
- [39] Wu, W., Hsiao, S. C., Carrico, Z. M. & Francis, M. B. Genome-free viral capsids as multivalent carriers for taxol delivery. *Angewandte Chemie (International ed. in English)* **48**, 9493–7 (2009). URL <http://www.ncbi.nlm.nih.gov/pubmed/19921725>.
-

- 
- [40] Ma, Y., Nolte, R. J. & Cornelissen, J. J. Virus-based nanocarriers for drug delivery. *Advanced Drug Delivery Reviews* **64**, 811–825 (2012). URL <https://www.sciencedirect.com/science/article/pii/S0169409X12000087>.
- [41] Fan, T., Yu, X., Shen, B. & Sun, L. Peptide Self-Assembled Nanostructures for Drug Delivery Applications. *Journal of Nanomaterials* **2017**, 1–16 (2017). URL <https://www.hindawi.com/journals/jnm/2017/4562474/>.
- [42] Habibi, N., Kamaly, N., Memic, A. & Shafiee, H. Self-assembled peptide-based nanostructures: Smart nanomaterials toward targeted drug delivery. *Nano Today* **11**, 41–60 (2016). URL <https://www.sciencedirect.com/science/article/pii/S1748013216300081>.
- [43] Yan, X., Zhu, P. & Li, J. Self-assembly and application of diphenylalanine-based nanostructures. *Chemical Society Reviews* **39**, 1877 (2010). URL <http://xlink.rsc.org/?DOI=b915765b>.
- [44] Silva, R. F., Araújo, D. R., Silva, E. R., Ando, R. A. & Alves, W. A. l-Diphenylalanine Microtubes As a Potential Drug-Delivery System: Characterization, Release Kinetics, and Cytotoxicity. *Langmuir* **29**, 10205–10212 (2013). URL <http://pubs.acs.org/doi/10.1021/la4019162>.
- [45] King, N. P. *et al.* Accurate design of co-assembling multi-component protein nanomaterials. *Nature* **510** (2014). URL <https://www.nature.com/nature/journal/v510/n7503/full/nature13404.html>.
- [46] Berman, H. M. *et al.* The protein data bank. *Nucleic Acids Research*, **28**: 235–242 (2000). URL <http://www.rcsb.org/>.
- [47] Yeates, T. O. Protein assembles into Archimedean geometry. *Nature* **569**, 340–342 (2019). URL <http://www.nature.com/articles/d41586-019-01407-z>.
- [48] Malay, A. D. *et al.* An ultra-stable gold-coordinated protein cage displaying reversible assembly. *Nature* **569**, 438–442 (2019). URL <http://www.nature.com/articles/s41586-019-1185-4>.
-

- 
- [49] Santos, R. *et al.* A comprehensive map of molecular drug targets. *Nature Reviews Drug Discovery* **16**, 19–34 (2017). URL <http://www.nature.com/articles/nrd.2016.230>.
- [50] Gordon, E., Mouz, N., Duée, E. & Dideberg, O. The crystal structure of the penicillin-binding protein 2x from *Streptococcus pneumoniae* and its acyl-enzyme form: implication in drug resistance. *Journal of Molecular Biology* **299**, 477–485 (2000). URL <https://www.sciencedirect.com/science/article/pii/S0022283600937409?via%3Dihub>.
- [51] Kapoor, G., Saigal, S. & Elongavan, A. Action and resistance mechanisms of antibiotics: A guide for clinicians. *Journal of anaesthesiology, clinical pharmacology* **33**, 300–305 (2017). URL <http://www.ncbi.nlm.nih.gov/pubmed/29109626>.
- [52] Birkegård, A. C., Halasa, T., Toft, N., Folkesson, A. & Græsbøll, K. Send more data: a systematic review of mathematical models of antimicrobial resistance. *Antimicrobial resistance and infection control* **7**, 117 (2018). URL <http://www.ncbi.nlm.nih.gov/pubmed/30288257>.
- [53] Niewiadomska, A. M. *et al.* Population-level mathematical modeling of antimicrobial resistance: a systematic review. *BMC Medicine* **17**, 81 (2019). URL <https://bmcmmedicine.biomedcentral.com/articles/10.1186/s12916-019-1314-9>.
- [54] O ’neill, J. TACKLING DRUG-RESISTANT INFECTIONS GLOBALLY: FINAL REPORT AND RECOMMENDATIONS THE REVIEW ON ANTIMICROBIAL RESISTANCE (2016). URL [https://amr-review.org/sites/default/files/160525\\_{\\_}Finalpaper\\_{\\_}withcover.pdf](https://amr-review.org/sites/default/files/160525_{_}Finalpaper_{_}withcover.pdf).
- [55] Delcour, A. H. Outer membrane permeability and antibiotic resistance. *Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics* **1794**, 808–816 (2009). URL <https://www.sciencedirect.com/science/article/pii/S1570963908003592?via%3Dihub>.
- [56] Vargiu, A. V. & Nikaido, H. Multidrug binding properties of the AcrB efflux pump characterized by molecular dynamics simulations. *Proceedings of the National Academy of Sciences of the United States of America*
-

- 109, 20637–42 (2012). URL <http://www.ncbi.nlm.nih.gov/pubmed/23175790>.
- [57] Kojima, S. & Nikaido, H. Permeation rates of penicillins indicate that *Escherichia coli* porins function principally as nonspecific channels. *Proceedings of the National Academy of Sciences* **110**, E2629–E2634 (2013). URL <http://www.pnas.org/cgi/doi/10.1073/pnas.1310333110>.
- [58] Tran, Q.-T., Williams, S., Farid, R., Erdemli, G. & Pearlstein, R. The translocation kinetics of antibiotics through porin OmpC: Insights from structure-based solvation mapping using WaterMap. *Proteins: Structure, Function, and Bioinformatics* **81**, 291–299 (2013). URL <http://doi.wiley.com/10.1002/prot.24185>.
- [59] Tamber, S. & Hancock, R. E. W. On the mechanism of solute uptake in *Pseudomonas*. *Frontiers in bioscience : a journal and virtual library* **8**, s472–83 (2003). URL <http://www.ncbi.nlm.nih.gov/pubmed/12700103>.
- [60] Baroud, M. *et al.* Underlying mechanisms of carbapenem resistance in extended-spectrum  $\beta$ -lactamase-producing *Klebsiella pneumoniae* and *Escherichia coli* isolates at a tertiary care centre in Lebanon: role of OXA-48 and NDM-1 carbapenemases. *International Journal of Antimicrobial Agents* **41**, 75–79 (2013). URL <https://linkinghub.elsevier.com/retrieve/pii/S0924857912003470>.
- [61] Lavigne, J.-P. *et al.* An adaptive response of *Enterobacter aerogenes* to imipenem: regulation of porin balance in clinical isolates. *International Journal of Antimicrobial Agents* **41**, 130–136 (2013). URL <https://linkinghub.elsevier.com/retrieve/pii/S0924857912004219>.
- [62] Poulou, A. *et al.* Outbreak Caused by an Ertapenem-Resistant, CTX-M-15-Producing *Klebsiella pneumoniae* Sequence Type 101 Clone Carrying an OmpK36 Porin Variant. *Journal of Clinical Microbiology* **51**, 3176–3182 (2013). URL <http://jcm.asm.org/cgi/doi/10.1128/JCM.01244-13>.
- [63] Wozniak, A. *et al.* Porin alterations present in non-carbapenemase-producing *Enterobacteriaceae* with high and intermediate levels of car-
-



- bapenem resistance in Chile. *Journal of Medical Microbiology* **61**, 1270–1279 (2012). URL <http://jmm.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.045799-0>.
- [64] Novais, Â. *et al.* Spread of an OmpK36-modified ST15 Klebsiella pneumoniae variant during an outbreak involving multiple carbapenem-resistant Enterobacteriaceae species and clones. *European Journal of Clinical Microbiology & Infectious Diseases* **31**, 3057–3063 (2012). URL <http://www.ncbi.nlm.nih.gov/pubmed/22706513><http://link.springer.com/10.1007/s10096-012-1665-z>.
- [65] Tangden, T., Adler, M., Cars, O., Sandegren, L. & Lowdin, E. Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model. *Journal of Antimicrobial Chemotherapy* **68**, 1319–1326 (2013). URL <http://www.ncbi.nlm.nih.gov/pubmed/23478794>.
- [66] Floyd, J. L., Smith, K. P., Kumar, S. H., Floyd, J. T. & Varela, M. F. LmrS Is a Multidrug Efflux Pump of the Major Facilitator Superfamily from Staphylococcus aureus. *Antimicrobial Agents and Chemotherapy* **54**, 5406–5412 (2010). URL <http://aac.asm.org/cgi/doi/10.1128/AAC.00580-10>.
- [67] Hu, R.-M., Liao, S.-T., Huang, C.-C., Huang, Y.-W. & Yang, T.-C. An Inducible Fusaric Acid Tripartite Efflux Pump Contributes to the Fusaric Acid Resistance in Stenotrophomonas maltophilia. *PLoS ONE* **7**, e51053 (2012). URL <https://dx.plos.org/10.1371/journal.pone.0051053>.
- [68] Kim, C. *et al.* The Mechanism of Heterogeneous Beta-Lactam Resistance in MRSA: Key Role of the Stringent Stress Response. *PLoS ONE* **8**, e82814 (2013). URL <http://dx.plos.org/10.1371/journal.pone.0082814>.
- [69] Ogawa, W., Onishi, M., Ni, R., Tsuchiya, T. & Kuroda, T. Functional study of the novel multidrug efflux pump KexD from Klebsiella pneumoniae. *Gene* **498**, 177–182 (2012). URL <https://linkinghub.elsevier.com/retrieve/pii/S0378111912002107>.
-

- 
- [70] Dolejska, M., Villa, L., Poirel, L., Nordmann, P. & Carattoli, A. Complete sequencing of an IncHI1 plasmid encoding the carbapenemase NDM-1, the ArmA 16S RNA methylase and a resistance-nodulation-cell division/multidrug efflux pump. *Journal of Antimicrobial Chemotherapy* **68**, 34–39 (2013). URL <https://academic.oup.com/jac/article/68/1/34/672511>.
- [71] Abouzeed, Y. M., Baucheron, S. & Cloeckaert, A. ramR mutations involved in efflux-mediated multidrug resistance in *Salmonella enterica* serovar Typhimurium. *Antimicrobial agents and chemotherapy* **52**, 2428–34 (2008). URL <http://www.ncbi.nlm.nih.gov/pubmed/18443112>.
- [72] Baucheron, S. *et al.* Bile-mediated activation of the acrAB and tolC multidrug efflux genes occurs mainly through transcriptional derepression of ramA in *Salmonella enterica* serovar Typhimurium. *Journal of Antimicrobial Chemotherapy* **69**, 2400–2406 (2014). URL <http://www.ncbi.nlm.nih.gov/pubmed/24816212>.
- [73] Nikaido, E., Shirosaka, I., Yamaguchi, A. & Nishino, K. Regulation of the AcrAB multidrug efflux pump in *Salmonella enterica* serovar Typhimurium in response to indole and paraquat. *Microbiology* **157**, 648–655 (2011). URL <http://mic.microbiologyresearch.org/content/journal/micro/10.1099/mic.0.045757-0>.
- [74] Hirakawa, H., Inazumi, Y., Masaki, T., Hirata, T. & Yamaguchi, A. Indole induces the expression of multidrug exporter genes in *Escherichia coli*. *Molecular Microbiology* **55**, 1113–1126 (2004). URL <http://doi.wiley.com/10.1111/j.1365-2958.2004.04449.x>.
- [75] Billal, D. S., Feng, J., Leprohon, P., Légaré, D. & Ouellette, M. Whole genome analysis of linezolid resistance in *Streptococcus pneumoniae* reveals resistance and compensatory mutations. *BMC Genomics* **12**, 512 (2011). URL <http://bmcbgenomics.biomedcentral.com/articles/10.1186/1471-2164-12-512>.
- [76] Gao, W. *et al.* Two Novel Point Mutations in Clinical *Staphylococcus aureus* Reduce Linezolid Susceptibility and Switch on the Stringent Response to Promote Persistent Infection. *PLoS Pathogens* **6**, e1000944 (2010). URL <http://dx.plos.org/10.1371/journal.ppat.1000944>.
-

- 
- [77] Shore, A. C. *et al.* Detection of Staphylococcal Cassette Chromosome *mec* Type XI Carrying Highly Divergent *mecA* , *mecI* , *mecR1* , *blaZ* , and *ccr* Genes in Human Clinical Isolates of Clonal Complex 130 Methicillin-Resistant *Staphylococcus aureus*. *Antimicrobial Agents and Chemotherapy* **55**, 3765–3773 (2011). URL <http://www.ncbi.nlm.nih.gov/pubmed/21636525>.
- [78] Katayama, Y., Ito, T. & Hiramatsu, K. A new class of genetic element, staphylococcus cassette chromosome *mec*, encodes methicillin resistance in *Staphylococcus aureus*. *Antimicrobial agents and chemotherapy* **44**, 1549–55 (2000). URL <http://www.ncbi.nlm.nih.gov/pubmed/10817707>.
- [79] Kumar, N. *et al.* Crystal structure of the transcriptional regulator Rv1219c of *Mycobacterium tuberculosis*. *Protein Science* **23**, 423–432 (2014). URL <http://doi.wiley.com/10.1002/pro.2424>.
- [80] Long, K. S., Poehlsgaard, J., Kehrenberg, C., Schwarz, S. & Vester, B. The Cfr rRNA Methyltransferase Confers Resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A Antibiotics. *Antimicrobial Agents and Chemotherapy* **50**, 2500–2505 (2006). URL <http://aac.asm.org/cgi/doi/10.1128/AAC.00131-06>.
- [81] Vetting, M. W. *et al.* Structure of QnrB1, a Plasmid-mediated Fluoroquinolone Resistance Factor. *Journal of Biological Chemistry* **286**, 25265–25273 (2011). URL <http://www.jbc.org/lookup/doi/10.1074/jbc.M111.226936>.
- [82] Abraham, E. P. & Chain, E. An enzyme from bacteria able to destroy penicillin. 1940. *Reviews of infectious diseases* **10**, 677–8 (1988). URL <http://www.ncbi.nlm.nih.gov/pubmed/3055168>.
- [83] Livermore, D. Defining an extended-spectrum  $\beta$ -lactamase. *Clinical Microbiology and Infection* **14**, 3–10 (2008). URL <https://linkinghub.elsevier.com/retrieve/pii/S1198743X14604717>.
- [84] Nordmann, P., Poirel, L., Walsh, T. R. & Livermore, D. M. The emerging NDM carbapenemases. *Trends in Microbiology* **19**, 588–
-

- 595 (2011). URL <https://linkinghub.elsevier.com/retrieve/pii/S0966842X11001776>.
- [85] Voulgari, E., Poulou, A., Koumaki, V. & Tsakris, A. Carbapenemase-producing *Enterobacteriaceae* : now that the storm is finally here, how will timely detection help us fight back? *Future Microbiology* **8**, 27–39 (2013). URL <https://www.futuremedicine.com/doi/10.2217/fmb.12.130>.
- [86] Woodford, N., Turton, J. F. & Livermore, D. M. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. *FEMS Microbiology Reviews* **35**, 736–755 (2011). URL <http://www.ncbi.nlm.nih.gov/pubmed/21303394>.
- [87] Woodford, N. & Johnson, A. P. Global spread of antibiotic resistance: the example of New Delhi metallo- $\beta$ -lactamase (NDM)-mediated carbapenem resistance. *Journal of Medical Microbiology* **62**, 499–513 (2013). URL <http://www.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.052555-0>.
- [88] Lynch, J. P., Clark, N. M. & Zhanel, G. G. Evolution of antimicrobial resistance among *Enterobacteriaceae* (focus on extended spectrum  $\beta$ -lactamases and carbapenemases). *Expert Opinion on Pharmacotherapy* **14**, 199–210 (2013). URL <http://www.tandfonline.com/doi/full/10.1517/14656566.2013.763030>.
- [89] Wright, G. Bacterial resistance to antibiotics: Enzymatic degradation and modification. *Advanced Drug Delivery Reviews* **57**, 1451–1470 (2005). URL <https://linkinghub.elsevier.com/retrieve/pii/S0169409X05000980>.
- [90] Norris, A. L. & Serpersu, E. H. Ligand promiscuity through the eyes of the aminoglycoside *N* 3 acetyltransferase IIa. *Protein Science* **22**, 916–928 (2013). URL <http://doi.wiley.com/10.1002/pro.2273>.
- [91] Qin, S. *et al.* Identification of a Novel Genomic Island Conferring Resistance to Multiple Aminoglycoside Antibiotics in *Campylobacter coli*. *Antimicrobial Agents and Chemotherapy* **56**, 5332 (2012). URL <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3457361/>.
-

- 
- [92] Mantravadi, P., Kalesh, K., Dobson, R., Hudson, A. & Parthasarathy, A. The Quest for Novel Antimicrobial Compounds: Emerging Trends in Research, Development, and Technologies. *Antibiotics* **8**, 8 (2019). URL <http://www.ncbi.nlm.nih.gov/pubmed/30682820>.
- [93] Bahar, A. A. & Ren, D. Antimicrobial peptides. *Pharmaceuticals (Basel, Switzerland)* **6**, 1543–75 (2013). URL <http://www.ncbi.nlm.nih.gov/pubmed/24287494>.
- [94] Mahlapuu, M., Håkansson, J., Ringstad, L. & Björn, C. Antimicrobial Peptides: An Emerging Category of Therapeutic Agents. *Frontiers in Cellular and Infection Microbiology* **6**, 194 (2016). URL <http://www.ncbi.nlm.nih.gov/pubmed/28083516>.
- [95] Zhang, L.-j. & Gallo, R. L. Antimicrobial peptides. *Current Biology* **26**, R14–R19 (2016). URL [#">https://www.sciencedirect.com/science/article/pii/S0960982215014098](https://www.sciencedirect.com/science/article/pii/S0960982215014098)#!
- [96] Ebbensgaard, A. *et al.* Comparative Evaluation of the Antimicrobial Activity of Different Antimicrobial Peptides against a Range of Pathogenic Bacteria. *PLOS ONE* **10**, e0144611 (2015). URL <http://dx.plos.org/10.1371/journal.pone.0144611>.
- [97] Brogden, K. A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? *Nature Reviews Microbiology* **3**, 238–250 (2005). URL <http://www.nature.com/articles/nrmicro1098>.
- [98] Hancock, R. E. W. & Sahl, H.-G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. *Nature Biotechnology* **24**, 1551–1557 (2006). URL <http://www.nature.com/articles/nbt1267>.
- [99] Malmsten, M. Interactions of Antimicrobial Peptides with Bacterial Membranes and Membrane Components. *Current topics in medicinal chemistry* **16**, 16–24 (2016). URL <http://www.ncbi.nlm.nih.gov/pubmed/26139113>.
- [100] Zhang, L., Rozek, A. & Hancock, R. E. Interaction of cationic antimicrobial peptides with model membranes. *The Journal of biological chemistry*
-

- 276**, 35714–22 (2001). URL <http://www.ncbi.nlm.nih.gov/pubmed/11473117>.
- [101] Schmitt, P., Rosa, R. D. & Destoumieux-Garzón, D. An intimate link between antimicrobial peptide sequence diversity and binding to essential components of bacterial membranes. *Biochimica et Biophysica Acta (BBA) - Biomembranes* **1858**, 958–970 (2016). URL <http://linkinghub.elsevier.com/retrieve/pii/S0005273615003430>.
- [102] Lin, T.-Y. & Weibel, D. B. Organization and function of anionic phospholipids in bacteria. *Applied Microbiology and Biotechnology* **100**, 4255–4267 (2016). URL <http://link.springer.com/10.1007/s00253-016-7468-x>.
- [103] Glukhov, E., Stark, M., Burrows, L. L. & Deber, C. M. Basis for selectivity of cationic antimicrobial peptides for bacterial versus mammalian membranes. *The Journal of biological chemistry* **280**, 33960–7 (2005). URL <http://www.ncbi.nlm.nih.gov/pubmed/16043484>.
- [104] Spector, A. A. & Yorek, M. A. Membrane lipid composition and cellular function. *Journal of lipid research* **26**, 1015–35 (1985). URL <http://www.ncbi.nlm.nih.gov/pubmed/3906008>.
- [105] van Meer, G., Voelker, D. R. & Feigenson, G. W. Membrane lipids: where they are and how they behave. *Nature reviews. Molecular cell biology* **9**, 112–24 (2008). URL <http://www.ncbi.nlm.nih.gov/pubmed/18216768>.
- [106] Yeaman, M. R. & Yount, N. Y. Mechanisms of Antimicrobial Peptide Action and Resistance. *Pharmacological Reviews* **55**, 27–55 (2003). URL <http://pharmrev.aspetjournals.org/cgi/doi/10.1124/pr.55.1.2>.
- [107] Lai, Y. & Gallo, R. L. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. *Trends in Immunology* **30**, 131–141 (2009). URL <https://www.sciencedirect.com/science/article/pii/S1471490609000052>.
- [108] Zasloff, M. Antimicrobial peptides of multicellular organisms. *Nature* **415**, 389–395 (2002). URL <http://www.ncbi.nlm.nih.gov/pubmed/11807545><http://www.nature.com/articles/415389a>.
-

- 
- [109] Matsuzaki, K. Control of cell selectivity of antimicrobial peptides. *Biochimica et Biophysica Acta (BBA) - Biomembranes* **1788**, 1687–1692 (2009). URL <https://www.sciencedirect.com/science/article/pii/S0005273608003076>.
- [110] Ebenhan, T., Gheysens, O., Kruger, H. G., Zeevaart, J. R. & Sathekge, M. M. Antimicrobial peptides: their role as infection-selective tracers for molecular imaging. *BioMed research international* **2014**, 867381 (2014). URL <http://www.ncbi.nlm.nih.gov/pubmed/25243191>.
- [111] Chan, D. I., Prenner, E. J. & Vogel, H. J. Tryptophan- and arginine-rich antimicrobial peptides: Structures and mechanisms of action. *Biochimica et Biophysica Acta (BBA) - Biomembranes* **1758**, 1184–1202 (2006). URL <http://linkinghub.elsevier.com/retrieve/pii/S0005273606001404>.
- [112] Toke, O. Antimicrobial peptides: New candidates in the fight against bacterial infections. *Biopolymers* **80**, 717–735 (2005). URL <http://doi.wiley.com/10.1002/bip.20286>.
- [113] Yang, L., Harroun, T. A., Weiss, T. M., Ding, L. & Huang, H. W. Barrel-stave model or toroidal model? A case study on melittin pores. *Biophysical journal* **81**, 1475–85 (2001). URL <http://www.ncbi.nlm.nih.gov/pubmed/11509361>.
- [114] Bertelsen, K., Dorosz, J., Hansen, S. K., Nielsen, N. C. & Vosegaard, T. Mechanisms of Peptide-Induced Pore Formation in Lipid Bilayers Investigated by Oriented <sup>31</sup>P Solid-State NMR Spectroscopy. *PLoS ONE* **7**, e47745 (2012). URL <http://dx.plos.org/10.1371/journal.pone.0047745>.
- [115] Lee, M.-T., Chen, F.-Y. & Huang, H. W. Energetics of Pore Formation Induced by Membrane Active Peptides <sup><sup></sup>. *Biochemistry* **43**, 3590–3599 (2004). URL <http://www.ncbi.nlm.nih.gov/pubmed/15035629>.</sup>
- [116] Spaar, A., Münster, C. & Salditt, T. Conformation of peptides in lipid membranes studied by x-ray grazing incidence scattering. *Biophys-*
-

- cal journal* **87**, 396–407 (2004). URL <http://www.ncbi.nlm.nih.gov/pubmed/15240474>.
- [117] Matsuzaki, K., Murase, O., Fujii, N. & Miyajima, K. An Antimicrobial Peptide, Magainin 2, Induced Rapid Flip-Flop of Phospholipids Coupled with Pore Formation and Peptide Translocation <sup><sup></sup>. *Biochemistry* **35**, 11361–11368 (1996). URL <http://www.ncbi.nlm.nih.gov/pubmed/8784191>.</sup>
- [118] Hallock, K. J., Lee, D.-K. & Ramamoorthy, A. MSI-78, an analogue of the magainin antimicrobial peptides, disrupts lipid bilayer structure via positive curvature strain. *Biophysical journal* **84**, 3052–60 (2003). URL <http://www.ncbi.nlm.nih.gov/pubmed/12719236>.
- [119] He, K., Ludtke, S. J., Huang, H. W. & Worcester, D. L. Antimicrobial peptide pores in membranes detected by neutron in-plane scattering. *Biochemistry* **34**, 15614–8 (1995). URL <http://www.ncbi.nlm.nih.gov/pubmed/7495788>.
- [120] Matsuzaki, K. *et al.* Relationship of Membrane Curvature to the Formation of Pores by Magainin 2 <sup><sup></sup>. *Biochemistry* **37**, 11856–11863 (1998). URL <https://pubs.acs.org/doi/10.1021/bi980539y>.</sup>
- [121] Matsuzaki, K., Sugishita, K.-i., Harada, M., Fujii, N. & Miyajima, K. Interactions of an antimicrobial peptide, magainin 2, with outer and inner membranes of Gram-negative bacteria. *Biochimica et Biophysica Acta (BBA) - Biomembranes* **1327**, 119–130 (1997). URL <https://www.sciencedirect.com/science/article/pii/S0005273697000515?via%3Dihub>.
- [122] Shai, Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by  $\alpha$ -helical antimicrobial and cell non-selective membrane-lytic peptides. *Biochimica et Biophysica Acta (BBA) - Biomembranes* **1462**, 55–70 (1999). URL <https://www.sciencedirect.com/science/article/pii/S000527369900200X?via%3Dihub>.
- [123] Ladokhin, A. S. & White, S. H. Detergent-like' permeabilization of anionic lipid vesicles by melittin. *Biochimica et Biophysica Acta*
-



- (*BBA*) - *Biomembranes* **1514**, 253–260 (2001). URL <https://www.sciencedirect.com/science/article/pii/S0005273601003820>.
- [124] Oren, Z. & Shai, Y. Mode of action of linear amphipathic  $\alpha$ -helical antimicrobial peptides. *Biopolymers* **47**, 451–463 (1998). URL <http://www.ncbi.nlm.nih.gov/pubmed/10333737>.
- [125] Gazit, E., Boman, A., Boman, H. G. & Shai, Y. Interaction of the mammalian antibacterial peptide cecropin P1 with phospholipid vesicles. *Biochemistry* **34**, 11479–88 (1995). URL <http://www.ncbi.nlm.nih.gov/pubmed/7547876>.
- [126] Yamaguchi, S. *et al.* Orientation and Dynamics of an Antimicrobial Peptide in the Lipid Bilayer by Solid-State NMR Spectroscopy. *Biophysical Journal* **81**, 2203–2214 (2001). URL <https://linkinghub.elsevier.com/retrieve/pii/S0006349501758687>.
- [127] Tang, M. & Hong, M. Structure and mechanism of  $\beta$ -hairpin antimicrobial peptides in lipid bilayers from solid-state NMR spectroscopy. *Molecular BioSystems* **5**, 317 (2009). URL <http://xlink.rsc.org/?DOI=b820398a>.
- [128] Lehrer, R. I. Primate defensins. *Nature Reviews Microbiology* **2**, 727–738 (2004). URL <http://www.nature.com/articles/nrmicro976>.
- [129] Fujii, G., Eisenberg, D. & Selsted, M. E. Defensins promote fusion and lysis of negatively charged membranes. *Protein Science* **2**, 1301–1312 (1993). URL <http://doi.wiley.com/10.1002/pro.5560020813>.
- [130] Kagan, B. L., Selsted, M. E., Ganz, T. & Lehrer, R. I. Antimicrobial defensin peptides form voltage-dependent ion-permeable channels in planar lipid bilayer membranes. *Proceedings of the National Academy of Sciences* **87**, 210–214 (1990). URL <http://www.pnas.org/cgi/doi/10.1073/pnas.87.1.210>.
- [131] Takeuchi, K. *et al.* Channel-forming membrane permeabilization by an antibacterial protein, sapecin: determination of membrane-buried and oligomerization surfaces by NMR. *The Journal of biological chemistry* **279**, 4981–7 (2004). URL <http://www.ncbi.nlm.nih.gov/pubmed/14630928>.
-

- 
- [132] Dathe, M. & Wieprecht, T. Structural features of helical antimicrobial peptides: their potential to modulate activity on model membranes and biological cells. *Biochimica et biophysica acta* **1462**, 71–87 (1999). URL <http://www.ncbi.nlm.nih.gov/pubmed/10590303>.
- [133] Yonezawa, A., Kuwahara, J., Fujii, N. & Sugiura, Y. Binding of tachyplesin I to DNA revealed by footprinting analysis: significant contribution of secondary structure to DNA binding and implication for biological action. *Biochemistry* **31**, 2998–3004 (1992). URL <http://pubs.acs.org/doi/abs/10.1021/bi00126a022>.
- [134] Gifford, J. L., Hunter, H. N. & Vogel, H. J. Lactoferricin. *Cellular and Molecular Life Sciences* **62**, 2588–2598 (2005). URL <http://link.springer.com/10.1007/s00018-005-5373-z>.
- [135] Tomita, M., Takase, M., Bellamy, W. & Shimamura, S. A review: the active peptide of lactoferrin. *Acta paediatrica Japonica : Overseas edition* **36**, 585–91 (1994). URL <http://www.ncbi.nlm.nih.gov/pubmed/7825467>.
- [136] Hwang, P. M., Zhou, N., Shan, X., Arrowsmith, C. H. & Vogel, H. J. Three-Dimensional Solution Structure of Lactoferricin B, an Antimicrobial Peptide Derived from Bovine Lactoferrin <sup></sup>. *Biochemistry* **37**, 4288–4298 (1998). URL <http://www.ncbi.nlm.nih.gov/pubmed/9521752>.
- [137] Schibli, D. J., Hwang, P. M. & Vogel, H. J. The structure of the antimicrobial active center of lactoferricin B bound to sodium dodecyl sulfate micelles. *FEBS Letters* **446**, 213–217 (1999). URL <http://doi.wiley.com/10.1016/S0014-5793{ }2899{ }2900214-8>.
- [138] Nguyen, L. T., Schibli, D. J. & Vogel, H. J. Structural studies and model membrane interactions of two peptides derived from bovine lactoferricin. *Journal of Peptide Science* **11**, 379–389 (2005). URL <http://doi.wiley.com/10.1002/psc.629>.
- [139] Peschel, A. & Sahl, H.-G. The co-evolution of host cationic antimicrobial peptides and microbial resistance. *Nature Reviews Microbiology* **4**, 529–536 (2006). URL <http://www.nature.com/articles/nrmicro1441>.
-

- 
- [140] Juhas, M. Horizontal gene transfer in human pathogens. *Critical Reviews in Microbiology* **41**, 101–108 (2015). URL <http://www.tandfonline.com/doi/full/10.3109/1040841X.2013.804031>.
- [141] Joo, H.-S., Fu, C.-I. & Otto, M. Bacterial strategies of resistance to antimicrobial peptides. *Philosophical transactions of the Royal Society of London. Series B, Biological sciences* **371** (2016). URL <http://www.ncbi.nlm.nih.gov/pubmed/27160595>.
- [142] Sieprawska-Lupa, M. *et al.* Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. *Antimicrobial agents and chemotherapy* **48**, 4673–9 (2004). URL <http://www.ncbi.nlm.nih.gov/pubmed/15561843>.
- [143] Teufel, P. & Götz, F. Characterization of an extracellular metalloprotease with elastase activity from Staphylococcus epidermidis. *Journal of Bacteriology* **175**, 4218 (1993). URL <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC204852/>.
- [144] Schmidtchen, A., Frick, I.-M., Andersson, E., Tapper, H. & Björck, L. Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. *Molecular Microbiology* **46**, 157–168 (2002). URL <http://doi.wiley.com/10.1046/j.1365-2958.2002.03146.x>.
- [145] Barańska-Rybak, W., Sonesson, A., Nowicki, R. & Schmidtchen, A. Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids. *Journal of Antimicrobial Chemotherapy* **57**, 260–265 (2006). URL <http://academic.oup.com/jac/article/57/2/260/804780/Glycosaminoglycans-inhibit-the-antibacterial>.
- [146] Nelson, D. C., Garbe, J. & Collin, M. Cysteine proteinase SpeB from Streptococcus pyogenes a potent modifier of immunologically important host and bacterial proteins. *Biological Chemistry* **392**, 1077–88 (2011). URL <https://www.degruyter.com/view/j/bchm.2011.392.issue-12/bc.2011.208/bc.2011.208.xml>.
- [147] Frick, I.-M. *et al.* Constitutive and Inflammation-Dependent Antimicrobial Peptides Produced by Epithelium Are Differentially Processed and Inactivated by the Commensal *Finnegoldia magna* and the
-

- Pathogen *Streptococcus pyogenes*. *The Journal of Immunology* **187**, 4300–4309 (2011). URL <http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.1004179>.
- [148] Selsted, M. E. & Harwig, S. S. Determination of the disulfide array in the human defensin HNP-2. A covalently cyclized peptide. *The Journal of biological chemistry* **264**, 4003–7 (1989). URL <http://www.ncbi.nlm.nih.gov/pubmed/2917986>.
- [149] Stumpe, S., Schmid, R., Stephens, D. L., Georgiou, G. & Bakker, E. P. Identification of OmpT as the protease that hydrolyzes the antimicrobial peptide protamine before it enters growing cells of *Escherichia coli*. *Journal of bacteriology* **180**, 4002–6 (1998). URL <http://www.ncbi.nlm.nih.gov/pubmed/9683502>.
- [150] Biegeleisen, K. The probable structure of the protamineDNA complex. *Journal of Theoretical Biology* **241**, 533–540 (2006). URL <https://linkinghub.elsevier.com/retrieve/pii/S0022519305005473>.
- [151] Sol, A. *et al.* Actin enables the antimicrobial action of LL-37 peptide in the presence of microbial proteases. *The Journal of biological chemistry* **289**, 22926–41 (2014). URL <http://www.ncbi.nlm.nih.gov/pubmed/24947511>.
- [152] Groisman, E. A., Parra-Lopez, C., Salcedo, M., Lipps, C. J. & Heffron, F. Resistance to host antimicrobial peptides is necessary for *Salmonella* virulence. *Proceedings of the National Academy of Sciences of the United States of America* **89**, 11939 (1992). URL <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC50673/>.
- [153] Parra-Lopez, C., Baer, M. T. & Groisman, E. A. Molecular genetic analysis of a locus required for resistance to antimicrobial peptides in *Salmonella typhimurium*. *The EMBO journal* **12**, 4053–62 (1993). URL <http://www.ncbi.nlm.nih.gov/pubmed/8223423>.
- [154] Mason, K. M., Munson, R. S., Jr. & Bakaletz, L. O. A Mutation in the sap Operon Attenuates Survival of Nontypeable *Haemophilus influenzae* in a Chinchilla Model of Otitis Media. *Infection and Immunity*
-

- 73**, 599 (2005). URL <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC538956/>.
- [155] Taggart, C. C. *et al.* Inactivation of Human  $\alpha$ -Defensins 2 and 3 by Elastolytic Cathepsins. *The Journal of Immunology* **171**, 931–937 (2003). URL <http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.171.2.931>.
- [156] Bokarewa, M. & Tarkowski, A. Human  $\alpha$ -defensins neutralize fibrinolytic activity exerted by staphylokinase. *Thrombosis and Haemostasis* **91**, 991–999 (2004). URL <http://www.ncbi.nlm.nih.gov/pubmed/15116261>.
- [157] Jin, T. *et al.* Staphylococcus aureus Resists Human Defensins by Production of Staphylokinase, a Novel Bacterial Evasion Mechanism. *The Journal of Immunology* **172**, 1169–1176 (2004). URL <http://www.ncbi.nlm.nih.gov/pubmed/14707093>.
- [158] Costerton, J. W., Stewart, P. S. & Greenberg, E. P. Bacterial biofilms: a common cause of persistent infections. *Science (New York, N.Y.)* **284**, 1318–22 (1999). URL <http://www.ncbi.nlm.nih.gov/pubmed/10334980>.
- [159] Jolivet-Gougeon, A. & Bonnaure-Mallet, M. Biofilms as a mechanism of bacterial resistance. *Drug Discovery Today: Technologies* **11**, 49–56 (2014). URL <https://linkinghub.elsevier.com/retrieve/pii/S1740674914000043>.
- [160] Nickel, J. C., Ruseska, I., Wright, J. B. & Costerton, J. W. Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material. *Antimicrobial agents and chemotherapy* **27**, 619–24 (1985). URL <http://www.ncbi.nlm.nih.gov/pubmed/3923925>.
- [161] Mah, T. F. & O'Toole, G. A. Mechanisms of biofilm resistance to antimicrobial agents. *Trends in microbiology* **9**, 34–9 (2001). URL <http://www.ncbi.nlm.nih.gov/pubmed/11166241>.
- [162] Wang, X., Preston, J. F. & Romeo, T. The pgaABCD locus of Escherichia coli promotes the synthesis of a polysaccharide adhesin required
-

- for biofilm formation. *Journal of bacteriology* **186**, 2724–34 (2004). URL <http://www.ncbi.nlm.nih.gov/pubmed/15090514>.
- [163] Vuong, C. *et al.* Polysaccharide intercellular adhesin (PIA) protects *Staphylococcus epidermidis* against major components of the human innate immune system. *Cellular microbiology* **6**, 269–75 (2004). URL <http://www.ncbi.nlm.nih.gov/pubmed/14764110>.
- [164] Vuong, C. *et al.* A crucial role for exopolysaccharide modification in bacterial biofilm formation, immune evasion, and virulence. *The Journal of biological chemistry* **279**, 54881–6 (2004). URL <http://www.ncbi.nlm.nih.gov/pubmed/15501828>.
- [165] Campos, M. A. *et al.* Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. *Infection and immunity* **72**, 7107–14 (2004). URL <http://www.ncbi.nlm.nih.gov/pubmed/15557634>.
- [166] Llobet, E., Tomas, J. M. & Bengoechea, J. A. Capsule polysaccharide is a bacterial decoy for antimicrobial peptides. *Microbiology* **154**, 3877–3886 (2008). URL <http://mic.microbiologyresearch.org/content/journal/micro/10.1099/mic.0.2008/022301-0>.
- [167] Batoni, G., Maisetta, G., Lisa Brancatisano, F., Esin, S. & Campa, M. Use of Antimicrobial Peptides Against Microbial Biofilms: Advantages and Limits. *Current Medicinal Chemistry* **18**, 256–279 (2011). URL <http://www.eurekaselect.com/openurl/content.php?genre=article{&issn=0929-8673{&volume=18{&issue=2{&spage=256>.
- [168] Strempel, N., Strehmel, J. & Overhage, J. Potential Application of Antimicrobial Peptides in the Treatment of Bacterial Biofilm Infections. *Current Pharmaceutical Design* **21**, 67–84 (2014). URL <http://www.eurekaselect.com/openurl/content.php?genre=article{&issn=1381-6128{&volume=21{&issue=1{&spage=67>.
- [169] Joo, H.-S. & Otto, M. Molecular Basis of In Vivo Biofilm Formation by Bacterial Pathogens. *Chemistry & Biology* **19**, 1503–1513 (2012). URL <https://linkinghub.elsevier.com/retrieve/pii/S1074552112004231>.
-

- 
- [170] Di Luca, M., Maccari, G. & Nifosì, R. Treatment of microbial biofilms in the post-antibiotic era: prophylactic and therapeutic use of antimicrobial peptides and their design by bioinformatics tools. *Pathogens and Disease* **70**, 257–270 (2014). URL <https://academic.oup.com/femspd/article-lookup/doi/10.1111/2049-632X.12151>.
- [171] Peschel, A. *et al.* Inactivation of the *dlt* operon in *Staphylococcus aureus* confers sensitivity to defensins, protegrins, and other antimicrobial peptides. *The Journal of biological chemistry* **274**, 8405–10 (1999). URL <http://www.ncbi.nlm.nih.gov/pubmed/10085071>.
- [172] Fabretti, F. *et al.* Alanine Esters of Enterococcal Lipoteichoic Acid Play a Role in Biofilm Formation and Resistance to Antimicrobial Peptides. *Infection and Immunity* **74**, 4164–4171 (2006). URL <http://www.ncbi.nlm.nih.gov/pubmed/16790791>.
- [173] Saar-Dover, R. *et al.* D-Alanylation of Lipoteichoic Acids Confers Resistance to Cationic Peptides in Group B *Streptococcus* by Increasing the Cell Wall Density. *PLoS Pathogens* **8**, e1002891 (2012). URL <http://dx.plos.org/10.1371/journal.ppat.1002891>.
- [174] Moskowitz, S. M., Ernst, R. K. & Miller, S. I. PmrAB, a two-component regulatory system of *Pseudomonas aeruginosa* that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. *Journal of bacteriology* **186**, 575–9 (2004). URL <http://www.ncbi.nlm.nih.gov/pubmed/14702327>.
- [175] Gunn, J. S. *et al.* PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. *Molecular microbiology* **27**, 1171–82 (1998). URL <http://www.ncbi.nlm.nih.gov/pubmed/9570402>.
- [176] Wang, X., Karbarz, M. J., McGrath, S. C., Cotter, R. J. & Raetz, C. R. H. MsbA transporter-dependent lipid A 1-dephosphorylation on the periplasmic surface of the inner membrane: topography of francisella novicida LpxE expressed in *Escherichia coli*. *The Journal of biological chemistry* **279**, 49470–8 (2004). URL <http://www.ncbi.nlm.nih.gov/pubmed/15339914>.
-

- 
- [177] Wang, X., McGrath, S. C., Cotter, R. J. & Raetz, C. R. H. Expression cloning and periplasmic orientation of the *Francisella novicida* lipid A 4'-phosphatase LpxF. *The Journal of biological chemistry* **281**, 9321–30 (2006). URL <http://www.ncbi.nlm.nih.gov/pubmed/16467300>.
- [178] Bugg, T. D. H. *et al.* Molecular basis for vancomycin resistance in *Enterococcus faecium* BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. *Biochemistry* **30**, 10408–10415 (1991). URL <http://pubs.acs.org/doi/abs/10.1021/bi00107a007>.
- [179] Brötz, H. *et al.* Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. *Molecular microbiology* **30**, 317–27 (1998). URL <http://www.ncbi.nlm.nih.gov/pubmed/9791177>.
- [180] Guo, L. *et al.* Lipid A acylation and bacterial resistance against vertebrate antimicrobial peptides. *Cell* **95**, 189–98 (1998). URL <http://www.ncbi.nlm.nih.gov/pubmed/9790526>.
- [181] Bishop, R. E. *et al.* Transfer of palmitate from phospholipids to lipid A in outer membranes of gram-negative bacteria. *The EMBO journal* **19**, 5071–80 (2000). URL <http://emboj.embopress.org/cgi/doi/10.1093/emboj/19.19.5071>.
- [182] Silhavy, T. J., Kahne, D. & Walker, S. The Bacterial Cell Envelope. *Cold Spring Harbor Perspectives in Biology* **2**, a000414–a000414 (2010). URL <http://www.ncbi.nlm.nih.gov/pubmed/20452953>.
- [183] Loutet, S. A., Flannagan, R. S., Kooi, C., Sokol, P. A. & Valvano, M. A. A complete lipopolysaccharide inner core oligosaccharide is required for resistance of *Burkholderia cenocepacia* to antimicrobial peptides and bacterial survival in vivo. *Journal of bacteriology* **188**, 2073–80 (2006). URL <http://www.ncbi.nlm.nih.gov/pubmed/16513737>.
- [184] Allen, C. A., Adams, L. G. & Ficht, T. A. Transposon-derived *Brucella abortus* rough mutants are attenuated and exhibit reduced intracellular survival. *Infection and immunity* **66**, 1008–16 (1998). URL <http://www.ncbi.nlm.nih.gov/pubmed/9488389>.
-



- 
- [185] Peschel, A. *et al.* *Staphylococcus aureus* Resistance to Human Defensins and Evasion of Neutrophil Killing via the Novel Virulence Factor MprF Is Based on Modification of Membrane Lipids with l-Lysine. *The Journal of Experimental Medicine* **193**, 1067–1076 (2001). URL <http://www.jem.org/lookup/doi/10.1084/jem.193.9.1067>.
- [186] Thedieck, K. *et al.* The MprF protein is required for lysinylation of phospholipids in listerial membranes and confers resistance to cationic antimicrobial peptides (CAMPs) on *Listeria monocytogenes*. *Molecular Microbiology* **62**, 1325–1339 (2006). URL <http://doi.wiley.com/10.1111/j.1365-2958.2006.05452.x>.
- [187] Klein, S. *et al.* Adaptation of *Pseudomonas aeruginosa* to various conditions includes tRNA-dependent formation of alanyl-phosphatidylglycerol. *Molecular Microbiology* **71**, 551–565 (2009). URL <http://doi.wiley.com/10.1111/j.1365-2958.2008.06562.x>.
- [188] Band, V. & Weiss, D. Mechanisms of Antimicrobial Peptide Resistance in Gram-Negative Bacteria. *Antibiotics* **4**, 18–41 (2014). URL <http://www.ncbi.nlm.nih.gov/pubmed/25927010>.
- [189] Kumariya, R., Sood, S. K., Rajput, Y. S., Saini, N. & Garsa, A. K. Increased membrane surface positive charge and altered membrane fluidity leads to cationic antimicrobial peptide resistance in *Enterococcus faecalis*. *Biochimica et biophysica acta* **1848**, 1367–75 (2015). URL <http://www.ncbi.nlm.nih.gov/pubmed/25782727>.
- [190] Raetz, C. R., Reynolds, C. M., Trent, M. S. & Bishop, R. E. Lipid A Modification Systems in Gram-Negative Bacteria. *Annual Review of Biochemistry* **76**, 295–329 (2007). URL <http://www.annualreviews.org/doi/10.1146/annurev.biochem.76.010307.145803>.
- [191] Wang, G. *et al.* APD3: the antimicrobial peptide database as a tool for research and education. *Nucleic Acids Research* **44**, D1087–D1093 (2016). URL <https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkv1278>.
- [192] Pirtskhalava, M. *et al.* DBAASP v.2: an enhanced database of structure and antimicrobial/cytotoxic activity of natural and synthetic peptides.
-

- Nucleic Acids Research* **44**, 6503–6503 (2016). URL <http://www.ncbi.nlm.nih.gov/pubmed/27060142>.
- [193] Jhong, J.-H. *et al.* dbAMP: an integrated resource for exploring antimicrobial peptides with functional activities and physicochemical properties on transcriptome and proteome data. *Nucleic Acids Research* **47**, D285–D297 (2019). URL <https://academic.oup.com/nar/article/47/D1/D285/5150231>.
- [194] Lata, S., Mishra, N. K. & Raghava, G. P. AntiBP2: improved version of antibacterial peptide prediction. *BMC Bioinformatics* **11**, S19 (2010). URL <http://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-11-S1-S19>.
- [195] Bhadra, P., Yan, J., Li, J., Fong, S. & Siu, S. W. I. AmPEP: Sequence-based prediction of antimicrobial peptides using distribution patterns of amino acid properties and random forest. *Scientific Reports* **8**, 1697 (2018). URL <http://www.nature.com/articles/s41598-018-19752-w>.
- [196] Fjell, C. D., Hiss, J. A., Hancock, R. E. W. & Schneider, G. Designing antimicrobial peptides: form follows function. *Nature Reviews Drug Discovery* **11**, 37 (2011). URL <http://www.nature.com/doifinder/10.1038/nrd3591>.
- [197] Wiradharma, N. *et al.* Synthetic cationic amphiphilic  $\alpha$ -helical peptides as antimicrobial agents. *Biomaterials* **32**, 2204–2212 (2011). URL <https://linkinghub.elsevier.com/retrieve/pii/S0142961210015097>.
- [198] Huang, Y., Huang, J. & Chen, Y. Alpha-helical cationic antimicrobial peptides: relationships of structure and function. *Protein & Cell* **1**, 143–152 (2010). URL <http://link.springer.com/10.1007/s13238-010-0004-3>.
- [199] Pag, U. *et al.* Analysis of in vitro activities and modes of action of synthetic antimicrobial peptides derived from an  $\alpha$ -helical sequence template'. *Journal of Antimicrobial Chemotherapy* **61**, 341–352
-

- (2008). URL <https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dkm479>.
- [200] Wang, J. *et al.* High specific selectivity and Membrane-Active Mechanism of the synthetic centrosymmetric  $\alpha$ -helical peptides with Gly-Gly pairs. *Scientific reports* **5**, 15963 (2015). URL <http://www.nature.com/articles/srep15963>.
- [201] Hilpert, K., Volkmer-Engert, R., Walter, T. & Hancock, R. E. W. High-throughput generation of small antibacterial peptides with improved activity. *Nature Biotechnology* **23**, 1008–1012 (2005). URL <http://www.nature.com/articles/nbt1113>.
- [202] Hilpert, K. *et al.* Sequence Requirements and an Optimization Strategy for Short Antimicrobial Peptides. *Chemistry & Biology* **13**, 1101–1107 (2006). URL <https://linkinghub.elsevier.com/retrieve/pii/S107455210600336X>.
- [203] Migoń, D. *et al.* Alanine Scanning Studies of the Antimicrobial Peptide Aurein 1.2. *Probiotics and Antimicrobial Proteins* 1–13 (2018). URL <http://link.springer.com/10.1007/s12602-018-9501-0>.
- [204] Grieco, P. *et al.* Alanine scanning analysis and structure-function relationships of the frog-skin antimicrobial peptide temporin-1Ta. *Journal of Peptide Science* **17**, 358–365 (2011). URL <http://doi.wiley.com/10.1002/psc.1350>.
- [205] Xie, J. *et al.* Potent effects of amino acid scanned antimicrobial peptide Feleucin-K3 analogs against both multidrug-resistant strains and biofilms of *Pseudomonas aeruginosa*. *Amino Acids* **50**, 1471–1483 (2018). URL <http://link.springer.com/10.1007/s00726-018-2625-4>.
- [206] Radziszhevsky, I. S. *et al.* Effects of acyl versus aminoacyl conjugation on the properties of antimicrobial peptides. *Antimicrobial agents and chemotherapy* **49**, 2412–20 (2005). URL <http://www.ncbi.nlm.nih.gov/pubmed/15917541>.
- [207] Serrano, G. N., Zhanel, G. G. & Schweizer, F. Antibacterial Activity of Ultrashort Cationic Lipopeptides. *Antimicrobial Agents and*
-

- Chemotherapy* **53**, 2215–2217 (2009). URL <http://www.ncbi.nlm.nih.gov/pubmed/19237652>.
- [208] Avrahami, D. & Shai, Y. A New Group of Antifungal and Antibacterial Lipopeptides Derived from Non-membrane Active Peptides Conjugated to Palmitic Acid. *Journal of Biological Chemistry* **279**, 12277–12285 (2004). URL <http://www.jbc.org/lookup/doi/10.1074/jbc.M312260200>.
- [209] Liu, S., Bao, J., Lao, X. & Zheng, H. Novel 3D Structure Based Model for Activity Prediction and Design of Antimicrobial Peptides. *Scientific Reports* **8**, 11189 (2018). URL <http://www.nature.com/articles/s41598-018-29566-5>.
- [210] Jiang, Z., Vasil, A. I., Gera, L., Vasil, M. L. & Hodges, R. S. Rational Design of  $\alpha$ -Helical Antimicrobial Peptides to Target Gram-negative Pathogens, *Acinetobacter baumannii* and *Pseudomonas aeruginosa*: Utilization of Charge, Specificity Determinants, Total Hydrophobicity, Hydrophobe Type and Location as Design Para. *Chemical Biology & Drug Design* **77**, 225–240 (2011). URL <http://doi.wiley.com/10.1111/j.1747-0285.2011.01086.x>.
- [211] Deslouches, B. *et al.* De Novo Generation of Cationic Antimicrobial Peptides: Influence of Length and Tryptophan Substitution on Antimicrobial Activity. *Antimicrobial Agents and Chemotherapy* **49**, 316–322 (2005). URL <http://www.ncbi.nlm.nih.gov/pubmed/15616311>.
- [212] Schmidt, N., Mishra, A., Lai, G. H. & Wong, G. C. Arginine-rich cell-penetrating peptides. *FEBS Letters* **584**, 1806–1813 (2010). URL <http://doi.wiley.com/10.1016/j.febslet.2009.11.046>.
- [213] Loose, C., Jensen, K., Rigoutsos, I. & Stephanopoulos, G. A linguistic model for the rational design of antimicrobial peptides. *Nature* **443**, 867–869 (2006). URL <http://www.nature.com/articles/nature05233>.
- [214] Cipcigan, F. *et al.* Accelerating molecular discovery through data and physical sciences: Applications to peptide-membrane interactions. *The Journal of Chemical Physics* **148**, 241744 (2018). URL <http://aip.scitation.org/doi/10.1063/1.5027261>.
-

- 
- [215] Bolintineanu, D. S. & Kaznessis, Y. N. Computational studies of protegrin antimicrobial peptides: A review. *Peptides* **32**, 188–201 (2011). URL <http://www.ncbi.nlm.nih.gov/pubmed/20946928>.
- [216] Khandelia, H. & Kaznessis, Y. N. Molecular dynamics simulations of helical antimicrobial peptides in SDS micelles: What do point mutations achieve? *Peptides* **26**, 2037–2049 (2005). URL <https://linkinghub.elsevier.com/retrieve/pii/S0196978105001610>.
- [217] Tsai, C.-W. *et al.* Coupling Molecular Dynamics Simulations with Experiments for the Rational Design of Indolicidin-Analogous Antimicrobial Peptides. *Journal of Molecular Biology* **392**, 837–854 (2009). URL <https://linkinghub.elsevier.com/retrieve/pii/S0022283609008031>.
- [218] Farrotti, A. *et al.* Molecular Dynamics Simulations of the Host Defense Peptide Temporin L and Its Q3K Derivative: An Atomic Level View from Aggregation in Water to Bilayer Perturbation. *Molecules* **22**, 1235 (2017). URL <http://www.mdpi.com/1420-3049/22/7/1235>.
- [219] Walters, W. P. & Goldman, B. B. Feature selection in quantitative structure-activity relationships. *Current opinion in drug discovery & development* **8**, 329–33 (2005). URL <http://www.ncbi.nlm.nih.gov/pubmed/15892248>.
- [220] Gonzalez, M., Teran, C., Saiz-Urra, L. & Teixeira, M. Variable Selection Methods in QSAR: An Overview. *Current Topics in Medicinal Chemistry* **8**, 1606–1627 (2008). URL <http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1568-0266&volume=8&issue=18&spage=1606>.
- [221] Wimley, W. C. Describing the Mechanism of Antimicrobial Peptide Action with the Interfacial Activity Model. *ACS Chemical Biology* **5**, 905–917 (2010). URL <http://www.ncbi.nlm.nih.gov/pubmed/20698568>.
- [222] Lewenza, S. Construction of a mini-Tn5-luxCDABE mutant library in *Pseudomonas aeruginosa* PAO1: A tool for identifying differentially regulated genes. *Genome Research* **15**, 583–589 (2005). URL <http://www.genome.org/cgi/doi/10.1101/gr.3513905>.
-

- 
- [223] Cherkasov, A. *et al.* Use of Artificial Intelligence in the Design of Small Peptide Antibiotics Effective against a Broad Spectrum of Highly Antibiotic-Resistant Superbugs. *ACS Chemical Biology* **4**, 65–74 (2009). URL <http://www.ncbi.nlm.nih.gov/pubmed/19055425>.
- [224] Lee, E. Y., Lee, M. W., Fulan, B. M., Ferguson, A. L. & Wong, G. C. L. What can machine learning do for antimicrobial peptides, and what can antimicrobial peptides do for machine learning? *Interface Focus* **7**, 20160153 (2017). URL <http://rsfs.royalsocietypublishing.org/lookup/doi/10.1098/rsfs.2016.0153>.
- [225] AB Naafs, M. The Antimicrobial Peptides: Ready for Clinical Trials? *Biomedical Journal of Scientific & Technical Research* **7**, 001–005 (2018). URL <https://biomedres.us/fulltexts/BJSTR.MS.ID.001536.php>.
- [226] Wipf, P., Xiao, J. & Stephenson, C. R. J. Peptide-Like Molecules (PLMs): A Journey from Peptide Bond Isosteres to Gramicidin S Mimetics and Mitochondrial Targeting Agents. *CHIMIA International Journal for Chemistry* **63**, 764–775 (2009). URL <http://www.ncbi.nlm.nih.gov/pubmed/20725595>.
- [227] Choudhary, A. & Raines, R. T. An Evaluation of Peptide-Bond Isosteres. *ChemBioChem* **12**, 1801–1807 (2011). URL <http://doi.wiley.com/10.1002/cbic.201100272>.
- [228] Anguela, X. M. & High, K. A. Entering the Modern Era of Gene Therapy. *Annual Review of Medicine* **70**, 273–288 (2019). URL <https://www.annualreviews.org/doi/10.1146/annurev-med-012017-043332>.
- [229] Barrangou, R. The roles of CRISPRCas systems in adaptive immunity and beyond. *Current Opinion in Immunology* **32**, 36–41 (2015). URL <http://www.ncbi.nlm.nih.gov/pubmed/25574773>.
- [230] Zhang, F., Wen, Y. & Guo, X. CRISPR/Cas9 for genome editing: progress, implications and challenges. *Human Molecular Genetics* **23**, R40–R46 (2014). URL <http://www.ncbi.nlm.nih.gov/pubmed/24651067>.
-

- 
- [231] Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering. *Cell* **157**, 1262–78 (2014). URL <http://www.ncbi.nlm.nih.gov/pubmed/24906146>.
- [232] Oldfield, E. H. *et al.* Gene Therapy for the Treatment of Brain Tumors Using Intra-Tumoral Transduction with the Thymidine Kinase Gene and Intravenous Ganciclovir. National Institutes of Health. *Human Gene Therapy* **4**, 39–69 (1993). URL <http://www.ncbi.nlm.nih.gov/pubmed/8384892>.
- [233] Lawler, S. E., Speranza, M.-C., Cho, C.-F. & Chiocca, E. A. Oncolytic Viruses in Cancer Treatment. *JAMA Oncology* **3**, 841 (2017). URL <http://www.ncbi.nlm.nih.gov/pubmed/27441411>.
- [234] Naldini, L. Ex vivo gene transfer and correction for cell-based therapies. *Nature Reviews Genetics* **12**, 301–315 (2011). URL <http://www.nature.com/articles/nrg2985>.
- [235] Mingozzi, F. & High, K. A. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. *Nature Reviews Genetics* **12**, 341–355 (2011). URL <http://www.nature.com/articles/nrg2988>.
- [236] Sánchez, L., Calvo, M. & Brock, J. H. Biological role of lactoferrin. *Archives of disease in childhood* **67**, 657–61 (1992). URL <http://www.ncbi.nlm.nih.gov/pubmed/1599309>.
- [237] Arnold, R., Cole, M. & McGhee, J. R. A bactericidal effect for human lactoferrin. *Science* **197**, 263–265 (1977). URL <http://www.ncbi.nlm.nih.gov/pubmed/327545>.
- [238] Arnold, R. R., Brewer, M. & Gauthier, J. J. Bactericidal activity of human lactoferrin: sensitivity of a variety of microorganisms. *Infection and immunity* **28**, 893–8 (1980). URL <http://www.ncbi.nlm.nih.gov/pubmed/6772569>.
- [239] Kirkpatrick, C. H., Green, I., Rich, R. R. & Schade, A. L. Inhibition of Growth of *Candida albicans* by Iron-Unsaturated Lactoferrin: Relation to Host-Defense Mechanisms in Chronic Mucocutaneous Candidiasis. *Journal of Infectious Diseases* **124**, 539–544
-

- (1971). URL <https://academic.oup.com/jid/article-lookup/doi/10.1093/infdis/124.6.539>.
- [240] Jahani, S., Shakiba, A. & Jahani, L. The Antimicrobial Effect of Lactoferrin on Gram-Negative and Gram-Positive Bacteria. *International Journal of Infection* **2** (2015). URL <http://intjinfection.com/en/articles/14726.html>.
- [241] Farnaud, S. & Evans, R. W. Lactoferrin—a multifunctional protein with antimicrobial properties. *Molecular immunology* **40**, 395–405 (2003). URL <http://www.ncbi.nlm.nih.gov/pubmed/14568385>.
- [242] Shau, H., Kim, A. & Golub, S. H. Modulation of natural killer and lymphokine-activated killer cell cytotoxicity by lactoferrin. *Journal of Leukocyte Biology* **51**, 343–349 (1992). URL <http://doi.wiley.com/10.1002/jlbb.51.4.343>.
- [243] Gahr, M., Speer, C. P., Damerau, B. & Sawatzki, G. Influence of Lactoferrin on the Function of Human Polymorphonuclear Leukocytes and Monocytes. *Journal of Leukocyte Biology* **49**, 427–433 (1991). URL <http://doi.wiley.com/10.1002/jlbb.49.5.427>.
- [244] Bellamy, W. *et al.* Identification of the bactericidal domain of lactoferrin. *Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology* **1121**, 130–136 (1992). URL <https://www.sciencedirect.com/science/article/pii/016748389290346F>.
- [245] Wakabayashi, H. *et al.* Cooperative anti-Candida effects of lactoferrin or its peptides in combination with azole antifungal agents. *Microbiology and immunology* **40**, 821–5 (1996). URL <http://www.ncbi.nlm.nih.gov/pubmed/8985937>.
- [246] Aguilera, O., Ostolaza, H., Quirós, L. & Fierro, J. Permeabilizing action of an antimicrobial lactoferricin-derived peptide on bacterial and artificial membranes. *FEBS Letters* **462**, 273–277 (1999). URL <https://www.sciencedirect.com/science/article/pii/S0014579399015458>.
- [247] Cochran, A. G., Skelton, N. J. & Starovasnik, M. A. Tryptophan zippers: Stable, monomeric  $\beta$ -hairpins. *Proceedings of the National Academy of*
-



- Sciences* **98**, 5578–5583 (2001). URL <https://www.pnas.org/content/98/10/5578>.
- [248] Tsutsumi, A. *et al.* Structure and orientation of bovine lactoferrampin in the mimetic bacterial membrane as revealed by solid-state NMR and molecular dynamics simulation. *Biophysical journal* **103**, 1735–43 (2012). URL <http://www.ncbi.nlm.nih.gov/pubmed/23083717>.
- [249] Arseneault, M., Bédard, S., Boulet-Audet, M. & Pérolet, M. Study of the Interaction of Lactoferricin B with Phospholipid Monolayers and Bilayers. *Langmuir* **26**, 3468–3478 (2010). URL <http://pubs.acs.org/doi/abs/10.1021/la903014w>.
- [250] Strøm, M. B. *et al.* Important structural features of 15-residue lactoferricin derivatives and methods for improvement of antimicrobial activity. *Biochemistry and cell biology = Biochimie et biologie cellulaire* **80**, 65–74 (2002). URL <http://www.ncbi.nlm.nih.gov/pubmed/11908644>.
- [251] Crombez, L. *et al.* A New Potent Secondary Amphipathic Cellpenetrating Peptide for siRNA Delivery Into Mammalian Cells. *Molecular Therapy* **17**, 95–103 (2009). URL <https://www.sciencedirect.com/science/article/pii/S1525001616314800?via=I3Dihub>.
- [252] Bustin, S. A. *et al.* The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. *Clinical chemistry* **55**, 611–22 (2009). URL <http://www.ncbi.nlm.nih.gov/pubmed/12142370>.
- [253] Elsabahy, M. *et al.* Surface Charges and Shell Crosslinks Each Play Significant Roles in Mediating Degradation, Biofouling, Cytotoxicity and Immunotoxicity for Polyphosphoester-based Nanoparticles. *Scientific Reports* **3**, 3313 (2013). URL <http://www.nature.com/articles/srep03313>.
-